drugset / Trial / NCT03345797

Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

NCT03345797

Phase 1 Terminated 8 enrolled Acerus Biopharma Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

PK study to evaluate serum levels of testosterone post nasal delivery in two cohorts of hypogonadal boys.

Timeline

Start
2018-03-01
Primary completion
2020-04-11
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 5.5 mg Intranasal
Subject Testosterone Small molecule 11 mg Intranasal

Indications